手术切除的小细胞肺癌患者中，程序性死亡配体1表达与良好的无病生存期相关。
Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
作者信息
Toyokawa Gouji, Takada Kazuki, Haratake Naoki, Takamori Shinkichi, Akamine Takaki, Katsura Masakazu, Fujishita Takatoshi, Shoji Fumihiro, Okamoto Tatsuro, Oda Yoshinao, Maehara Yoshihiko
机构信息
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
出版信息
Anticancer Res. 2016 Aug;36(8):4329-36.
BACKGROUND
The prognostic significance of programmed death ligand 1 (PD-L1) has been reported in non-small cell lung cancer; however, the significance of PD-L1 expression in patients with resected small-cell lung cancer (SCLC) remains to be clarified.
MATERIALS AND METHODS
Forty patients with SCLC whose resected specimens were available for immunohistochemistry for PD-L1 were evaluated to determine the association between its expression and the clinicopathological factors and prognosis.
RESULTS
Among 40 patients, PD-L1 was expressed in tumor cells (TCs) of six (15%), tumor-infiltrating cells (ICs) of 16 (40%), and TCs and/or ICs cells of 18 (45%) patients. Patients with PD-L1-positve ICs and TCs and/or ICs exhibited significantly longer disease-free survival than those without PD-L1-expression (hazard ratio (HR)=0.268; 95% confidence interval (CI)=0.100-0.645; p=0.003 and HR=0.301; 95% CI=0.118-0.702; p=0.005, respectively).
CONCLUSION
This study provides important evidence on the prognostic value of the PD-L1 expression in resected SCLC patients.
背景
程序性死亡配体1（PD-L1）在非小细胞肺癌中的预后意义已有报道；然而，PD-L1表达在接受手术切除的小细胞肺癌（SCLC）患者中的意义仍有待阐明。
材料与方法
对40例手术切除标本可用于PD-L1免疫组织化学检测的SCLC患者进行评估，以确定其表达与临床病理因素及预后之间的关联。
结果
40例患者中，6例（15%）肿瘤细胞（TCs）、16例（40%）肿瘤浸润细胞（ICs）以及18例（45%）患者的TCs和/或ICs表达PD-L1。PD-L1阳性ICs以及TCs和/或ICs的患者无病生存期显著长于无PD-L1表达的患者（风险比（HR）=0.268；95%置信区间（CI）=0.100 - 0.645；p = 0.003以及HR = 0.301；95% CI = 0.118 - 0.702；p = 0.005）。
结论
本研究为PD-L1表达在接受手术切除的SCLC患者中的预后价值提供了重要证据。
Zotero 插件